http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004137487-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 |
| filingDate | 2003-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7ecd68913eac55eca9b45a79408fc4c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_73c3f2f1d0295442044ae47b07a95c60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0674a192517cd2861fed928381cb4ee9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af40a9f2f0170923b939652a14e9ade3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec8dbc853f070e5ab8a00a18d71ff341 |
| publicationDate | 2004-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2004137487-A1 |
| titleOfInvention | hKCa3/KCNN3 small conductance calcium activated potassium channel: a diagnostic marker and therapeutic target |
| abstract | The present invention is based on the discovery and cloning of the human small conductance calcium activated potassium channel type 3 (hKCa3/KCNN3) gene, which is expressed in neuronal cells, skeletal muscle, heart, and lymphocytes. Alterations in the hKCa3/KCNN3 gene or its protein product may enhance susceptibility to schizophrenia and/or bipolar disorder. hKCa3/KCNN3 may be involved in neuropsychiatric, neurological, neuromuscular, and immunological disorders. Substantially purified hKCa3/KCNN3 polypeptides and polynucleotides are provided. Antibodies which bind to hKCa3/KCNN3 polypeptides are also disclosed. A method for identifying a compound which affects hKCa3/KCNN3 polynucleotide or polypeptide is provided. A method for diagnosis and determining the prognosis and treatment regimen of a subject having or at risk of having a hKCa3/KCNN3-associated disorder is also provided. A method of treating a subject having or at risk of having an hKCa3/KCNN3-associated disorder by administering a therapeutically effective amount of a polynucleotide encoding SEQ ID NO:2 is also provided. A formulation for administration of hKCa3/KCNN3 to a patient of a therapeutically effective amount of hKCa3/KCNN3 polypeptide is provided. Kits useful for detecting the presence of hKCa3/KCNN3 polypeptide or polynucleotide in a sample from a subject having a hKCa3/KCNN3-associated disorder are provided. Transgenic nonhuman animals having a transgene encoding hKCa3/KCNN3 are also described. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7829113-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011081404-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8758810-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006222696-A1 |
| priorityDate | 1997-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1151.